{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:04:57Z","timestamp":1783919097377,"version":"3.55.0"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011493","name":"Taizhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["TS202411"],"award-info":[{"award-number":["TS202411"]}],"id":[{"id":"10.13039\/501100011493","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor-related pneumonitis (CIP) is an important pulmonary toxicity in cancer immunotherapy. Its diagnostic assessment is difficult because symptoms and imaging overlap with infection, radiation pneumonitis, tumor progression, pre-existing interstitial lung disease, and other drug-induced lung injuries. Although publications on CIP have increased in recent years, research on diagnostic assessment remains insufficiently described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publications on CIP and diagnostic assessment were retrieved from the Web of Science Core Collection (WoSCC) and PubMed. After screening, 628 WoSCC records were included as the main dataset for bibliometric analysis, and 74 PubMed records were used for supplementary clinical-topic assessment. Microsoft Excel, VOSviewer, CiteSpace, Bibliometrix, and SCImago Graphica were used to examine publication trends, country and institutional contributions, author collaboration, journal distribution, keyword co-occurrence, clustering, burst terms, and PubMed-based diagnostic topic classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CIP research was sparse before 2015, increased after 2015, and accelerated after 2019, with the highest annual output observed in 2023. China published the highest number of papers, while the United States has the greatest citation impact. Institutional and author analysis identified active research groups mainly from China, the United States and Japan. Research is mainly published in oncology, immunology, thoracic medicine and respiratory journals. Keyword analysis shows a shift from melanoma, T cells and immune checkpoint inhibition towards clinically focused themes, including diagnosis, differential diagnosis, imaging features, bronchoalveolar lavage (BAL), biomarkers, risk factors and nomogram-based prediction. A supplementary PubMed analysis similarly highlights imaging features, BAL, bronchoscopy or pathological assessment, and risk prediction as the primary clinical diagnostic themes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Research into CIP has evolved from the recognition of immune-related pulmonary toxicity to diagnostic assessment, differential diagnosis and personalised risk assessment. Current diagnostic studies reflect the clinical challenge of distinguishing CIP from other pulmonary complications in patients receiving immunotherapy. Future research should focus on developing and validating standardised, multicenter diagnostic strategies linked to prognosis. Current research trends suggest that imaging findings, bronchoalveolar lavage fluid or histopathological assessment, biomarkers, baseline lung function, and predictive models may form key components of such strategies; however, their clinical utility requires validation through prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1885789","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:23:59Z","timestamp":1783916639000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic research in immune checkpoint inhibitor-related pneumonitis: a bibliometric analysis of research evolution, diagnostic focuses, and future priorities"],"prefix":"10.3389","volume":"16","author":[{"given":"Luwei","family":"Han","sequence":"first","affiliation":[{"name":"Dalian Medical University","place":["Dalian, China"]},{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Dalian Medical University","place":["Dalian, China"]},{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Fang","sequence":"additional","affiliation":[{"name":"Dalian Medical University","place":["Dalian, China"]},{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyang","family":"Fei","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaohua","family":"Han","sequence":"additional","affiliation":[{"name":"Dalian Medical University","place":["Dalian, China"]},{"name":"Department of Oncology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1792179","article-title":"Inferring tumor immune microenvironment -related risk states from pretreatment H&E pathomics and clinical biomarkers to predict checkpoint inhibitor pneumonitis in advanced NSCLC: a multicenter multimodal study","volume":"17","author":"Yuan","year":"2026","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61071258","article-title":"Risk factors and biomarkers for pulmonary toxicities associated with immune checkpoint inhibitors","volume":"61","author":"Guzel","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2024.02.006","article-title":"Drug-induced lung disease in the oncology patient: from cytotoxic agents to immunotherapy","volume":"45","author":"Shroff","year":"2024","journal-title":"Clin Chest Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/17476348.2025.2538273","article-title":"Pneumonitis induced by immune checkpoint inhibitors: a systematic review","volume":"20","author":"Casal","year":"2026","journal-title":"Expert Rev Respir Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02732-2","article-title":"High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study","volume":"30","author":"Ishida","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11912-020-00920-z","article-title":"Checkpoint inhibitor pneumonitis: mechanisms, characteristics, management strategies, and beyond","volume":"22","author":"Reuss","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021203427","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society","volume":"298","author":"Johkoh","year":"2021","journal-title":"Radiology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.radonc.2021.01.001","article-title":"Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer","volume":"157","author":"Cousin","year":"2021","journal-title":"Radiother Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1159\/000543556","article-title":"Characteristics and risk factors of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: a retrospective study","volume":"103","author":"Cui","year":"2025","journal-title":"Oncology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021203427","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society","volume":"159","author":"Johkoh","year":"2021","journal-title":"Chest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231206705","article-title":"The predictive model construction for immune-related adverse events in non-small cell lung cancer patients receiving immunotherapy","volume":"22","author":"Gao","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"B12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cllc.2019.07.006","article-title":"Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors","volume":"20","author":"Fukihara","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000515","article-title":"Clinical manifestation, risk factors, and immune checkpoint inhibitor rechallenge of checkpoint inhibitor-associated pneumonitis in patients with lung cancer","volume":"47","author":"Li","year":"2024","journal-title":"J Immunother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1145143","article-title":"Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients","volume":"13","author":"Liu","year":"2023","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246236","article-title":"Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients with locally advanced non-small-cell lung cancer","volume":"14","author":"Daido","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12575-025-00287-0","article-title":"Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies","volume":"27","author":"Yang","year":"2025","journal-title":"Biol Proced Online"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.998516","article-title":"Case report: pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-020-01667-0","article-title":"Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma","volume":"132","author":"Beer","year":"2020","journal-title":"Wien Klin Wochenschr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1186\/s12885-025-15105-9","article-title":"The incidence and risk factors of pulmonary infection complications in lung cancer patients treated with immune checkpoint inhibitors","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04696-0","article-title":"Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis","volume":"149","author":"Wang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5570","article-title":"Anti-PD-1\/PD-L1 and anti-CTLA-4 associated checkpoint inhibitor pneumonitis in non-small cell lung cancer: occurrence, pathogenesis and risk factors (review)","volume":"63","author":"Hu","year":"2023","journal-title":"Int J Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-024-00599-y","article-title":"Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors","volume":"25","author":"Wang","year":"2024","journal-title":"BMC Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020302","article-title":"Biomarkers associated with immune-related adverse events under checkpoint inhibitors in metastatic melanoma","volume":"14","author":"Wolffer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa081","article-title":"Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis","volume":"66","author":"von Itzstein","year":"2020","journal-title":"Clin Chem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2022.04.010","article-title":"FDG PET\/CT for evaluation of immunotherapy response in lung cancer patients","volume":"52","author":"Leger","year":"2022","journal-title":"Semin Nucl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1138489","article-title":"Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning","volume":"14","author":"Gong","year":"2023","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/ms9.0000000000002436","article-title":"A pocket practical guide on bibliometric analysis: bridging informatics with science in a rapid manner","volume":"86","author":"Li","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1586\/era.10.144","article-title":"Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma","volume":"10","author":"Peggs","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3922","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11324","article-title":"Association between imaging findings of airway obstruction adjacent to lung tumors and the onset of interstitial lung disease after nivolumab","volume":"32","author":"Nakahama","year":"2018","journal-title":"In Vivo"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2017170085","article-title":"Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings","volume":"37","author":"Wang","year":"2017","journal-title":"Radiographics"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1582714","article-title":"Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitis","volume":"12","author":"Mir","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s00262-025-04053-9","article-title":"Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis","volume":"74","author":"Hazim","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220921543","article-title":"Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab","volume":"27","author":"Kethireddy","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-024-00618-3","article-title":"Value of 2-[18F]FDG-PET\/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review","volume":"12","author":"Nadaraja","year":"2024","journal-title":"Clin Transl Imaging"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153966","article-title":"Therapeutic and adverse effect of anti-PD1 immunotherapy in melanoma: a retrospective, single-institute study of 222 patients","volume":"15","author":"Eikenes","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.07.003","article-title":"Pneumonitis after concurrent chemoradiation and immune checkpoint inhibition in patients with locally advanced non-small cell lung cancer","volume":"35","author":"Altan","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01257-6","article-title":"Management of pulmonary toxicities associated with systemic therapy in non small cell lung cancer","volume":"25","author":"Velimirovic","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.10.012","article-title":"Clinical characteristics and management of checkpoint inhibitor pneumonitis in non-small-cell lung cancer patients after neoadjuvant immunotherapy","volume":"26","author":"Jiang","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2024-0027","article-title":"Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management","volume":"58","author":"Kovac","year":"2024","journal-title":"Radiol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2025.0133","article-title":"Serial KL-6 changes in PD-1\/PD-L1 inhibitor-related pneumonitis in non-small cell lung cancer: a single-center prospective pilot study","volume":"89","author":"Sim","year":"2026","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2025.02.005","article-title":"Utility of serum Krebs von den Lungen-6 and surfactant protein-D levels for the diagnosis of immune checkpoint inhibitor-induced immune-related pneumonitis","volume":"63","author":"Nakai","year":"2025","journal-title":"Respir Investig"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1454114","article-title":"Clinical characteristics and biomarkers of severe immune checkpoint inhibitor-related pneumonitis triggered by immunotherapy followed by radiation: a case report","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1249511","article-title":"Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept","volume":"14","author":"Aminu","year":"2023","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1480183","article-title":"Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma","volume":"15","author":"Farooqi","year":"2024","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2024.09.053","article-title":"Radiomics biomarkers to predict checkpoint inhibitor pneumonitis in non-small cell lung cancer","volume":"32","author":"Du","year":"2025","journal-title":"Acad Radiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa'ak","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840313","article-title":"Interleukin-10 is a promising marker for immune-related adverse events in patients with non-small cell lung cancer receiving immunotherapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1745842","article-title":"Research on microbial communities in tumor microenvironments: cutting-edge dynamics and future trends from a bibliometric perspective","volume":"17","author":"Tang","year":"2026","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2024.08.043","article-title":"(18)F-FDG-PET\/CT uptake by noncancerous lung as a predictor of interstitial lung disease induced by immune checkpoint inhibitors","volume":"32","author":"Yamazaki","year":"2025","journal-title":"Acad Radiol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16111990","article-title":"Is (18)F-FDG-PET\/CT an optimal imaging modality for detecting immune-related adverse events after immune-checkpoint inhibitor therapy? Pros and cons","volume":"16","author":"Karlsen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02840-9","article-title":"Diagnostic impact of (18)F-FDG PET\/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy","volume":"24","author":"Tatar","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12885-024-12008-z","article-title":"Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220073","article-title":"Interstitial lung abnormalities at CT: subtypes, clinical significance, and associations with lung cancer","volume":"42","author":"Hata","year":"2022","journal-title":"Radiographics"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1177\/15330338251344004","article-title":"Machine learning model integrating CT radiomics of the lung to predict checkpoint inhibitor pneumonitis in patients with advanced cancer","volume":"24","author":"Cousin","year":"2025","journal-title":"Technol Cancer Res Treat"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.20.22837","article-title":"A review of the mechanisms and clinical implications of precision cancer therapy-related toxicity: a primer for the radiologist","volume":"215","author":"Thomas","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15433","article-title":"A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: a case report","volume":"15","author":"Koi","year":"2024","journal-title":"Thorac Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2021.05.009","article-title":"Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: multi-institutional research in Japan","volume":"29","author":"Oshiro","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4355636","article-title":"Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer","volume":"9","author":"Fukuda","year":"2023","journal-title":"Heliyon"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15010251","article-title":"Mixed infectious-immune pneumonitis associated with PD-L1 blockade: a case of durvalumab-induced lung injury complicated by human metapneumovirus infection","volume":"15","author":"Pipito","year":"2025","journal-title":"J Clin Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12967-023-04212-5","article-title":"Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy","volume":"21","author":"Chen","year":"2023","journal-title":"J Transl Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.828858","article-title":"Dosimetric risk factors for acute radiation pneumonitis in patients with prior receipt of immune checkpoint inhibitors","volume":"12","author":"Bi","year":"2021","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13014-021-01930-2","article-title":"Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study","volume":"16","author":"Jang","year":"2021","journal-title":"Radiat Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110047","article-title":"Integration of dosimetric parameters, clinical factors, and radiomics to predict symptomatic radiation pneumonitis in lung cancer patients undergoing combined immunotherapy and radiotherapy","volume":"190","author":"Nie","year":"2024","journal-title":"Radiotherapy Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.611810","article-title":"Case report: Pseudoprogression with nivolumab and bevacizumab followed by recurrent immune-related pneumonitis in urothelial carcinoma with lung metastasis","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/his.14704","article-title":"Immune check-point inhibitor-related pneumonitis: acute lung injury with rapid progression and organising pneumonia with less severe clinical disease","volume":"81","author":"Imran","year":"2022","journal-title":"Histopathology"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2025-292","article-title":"Expert consensus on cancer treatment-related lung injury","volume":"17","author":"Lin","year":"2025","journal-title":"J Thorac Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109275","article-title":"Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors","volume":"132","author":"Park","year":"2020","journal-title":"Eur J Radiol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13244-024-01771-z","article-title":"The radiologist's role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review","volume":"15","author":"Dinkel","year":"2024","journal-title":"Insights Imaging"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1150751","article-title":"Differential diagnosis of pulmonary sarcoidosis: a review","volume":"10","author":"Valeyre","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.14423\/smj.0000000000001166","article-title":"Immune checkpoint inhibitor-related pulmonary toxicity: focus on nivolumab","volume":"113","author":"Bukamur","year":"2020","journal-title":"South Med J"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10649-0","article-title":"Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"23","author":"Pang","year":"2023","journal-title":"BMC Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4251\/wjgo.v15.i5.892","article-title":"Acute respiratory distress syndrome and severe pneumonitis after atezolizumab plus bevacizumab for hepatocellular carcinoma treatment: a case report","volume":"15","author":"Cho","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1159\/000529204","article-title":"Immune checkpoint inhibitor-related pneumonitis in lung cancer patients with interstitial lung disease: significance of radiological pleuroparenchymal fibroelastosis","volume":"101","author":"Osaki","year":"2023","journal-title":"Oncology"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17895","article-title":"Radiological assessment of immunotherapy effects and immune checkpoint\u2010related pneumonitis for lung cancer","volume":"28","author":"Hu","year":"2023","journal-title":"J Cell Mol Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1183\/13993003.congress-2024.oa3786","article-title":"Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B83","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s00262-024-03902-3","article-title":"Cytokine profile of bronchoalveolar lavage in patients with and without checkpoint inhibitor pneumonitis","volume":"74","author":"Ploch","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1097\/mcp.0000000000001175","article-title":"Immune checkpoint inhibitor-associated pneumonitis: focus on diagnosis and underlying mechanisms","volume":"31","author":"Khoury","year":"2025","journal-title":"Curr Opin Pulmonary Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.590494","article-title":"Distinct immunophenotypes of T cells in bronchoalveolar lavage fluid from leukemia patients with immune checkpoint inhibitors-related pulmonary complications","volume":"11","author":"Kim","year":"2020","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106688","article-title":"Not all bad: drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival","volume":"111","author":"Wei","year":"2021","journal-title":"Leuk Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-025-05905-w","article-title":"Clinical features of immune checkpoint inhibitor-related pneumonitis in older patients with lung cancer receiving immune checkpoint inhibitors-based therapy: a retrospective study","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Geriatrics"},{"key":"B88","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00428-024-03976-5","article-title":"Clinical and histopathological features of immune checkpoint inhibitor-induced lung toxicity","volume":"487","author":"Rolim","year":"2025","journal-title":"Virchows Arch"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad118","article-title":"Incidence and risk factors for pneumonitis associated with checkpoint inhibitors in advanced non-small cell lung cancer: a single center experience","volume":"28","author":"Altan","year":"2023","journal-title":"Oncologist"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2026.1730022","article-title":"Metagenomic next-generation sequencing for diagnosis of immune checkpoint inhibitor-associated pneumonitis: a retrospective comparative clinical performance study","volume":"16","author":"Jiang","year":"2026","journal-title":"Front Cell Infect Microbiol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00659","article-title":"Tuberculosis infection in a patient treated with nivolumab for non-small cell lung cancer: case report and literature review","volume":"9","author":"van Eeden","year":"2019","journal-title":"Front Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7059","article-title":"Association between pretreatment chest imaging and immune checkpoint inhibitor pneumonitis among patients with lung cancer","volume":"21","author":"Wong","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B93","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-019-02431-8","article-title":"Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody","volume":"69","author":"Shibaki","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B94","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00262-024-03792-5","article-title":"Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities","volume":"73","author":"Kikuchi","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.08.018","article-title":"A phase 2 study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis","volume":"15","author":"Ikeda","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2025.2469375","article-title":"Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients","volume":"14","author":"Greib","year":"2025","journal-title":"Oncoimmunology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03281-7","article-title":"Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study","volume":"72","author":"Sawa","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107330","article-title":"Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis","volume":"217","author":"Stahlbaum","year":"2023","journal-title":"Respir Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.08.014","article-title":"Impact of baseline interstitial lung abnormalities on pneumonitis risk in patients receiving immune checkpoint inhibitors for non-small-cell lung cancer","volume":"24","author":"Petranovic","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"B101","doi-asserted-by":"publisher","first-page":"570233","DOI":"10.3389\/fonc.2020.570233","article-title":"Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy","volume":"10","author":"Barron","year":"2020","journal-title":"Front Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010114","article-title":"Krebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis","volume":"12","author":"Matsukane","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1372532","article-title":"The prognostic impact of severe grade immune checkpoint inhibitor related pneumonitis in non-small cell lung cancer patients","volume":"14","author":"Sun","year":"2024","journal-title":"Front Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15385","article-title":"Risk factors for severe immune\u2010related pneumonitis after nivolumab plus ipilimumab therapy for non\u2010small cell lung cancer","volume":"15","author":"Sumi","year":"2024","journal-title":"Thorac Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00520-026-10448-w","article-title":"High-grade immune-related adverse events resulting from immune checkpoint inhibitor treatment: Evaluation of diagnostics and outcomes in admitted patients","volume":"34","author":"Legakis","year":"2026","journal-title":"Support Care Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11618","article-title":"Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer","volume":"20","author":"Wang","year":"2020","journal-title":"Oncol Lett"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1668092\/v1","article-title":"Comprehensive nomogram models for predicting checkpoint inhibitor pneumonitis","volume":"13","author":"Jia","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012444","article-title":"Metagenomic next-generation sequencing unraveled the characteristic of lung microbiota in patients with checkpoint inhibitor pneumonitis: Results from a prospective cohort study","volume":"13","author":"Zhou","year":"2025","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1885789\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:24:02Z","timestamp":1783916642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1885789\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":108,"alternative-id":["10.3389\/fonc.2026.1885789"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1885789","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"article-number":"1885789"}}